SMAD2 and pulmonary fibrosis: Treatment with the SIRT2 inhibitor AGK2 significantly attenuated the degree of pulmonary fibrosis and reduced the phosphorylation of Smad2/3; therefore, SIRT2 may be involved in IPF development by regulating the Smad2/3 pathway (73).